New Prevention Study Coming Soon
Can teplizumab prevent or delay type 1 diabetes?
A new TrialNet study will test whether treatment with a drug called teplizumab, also known as anti-CD3 mAb, can prevent or delay type 1 diabetes in high-risk (autoantibody positive) relatives of people with type 1 diabetes.

Study for Newly Diagnosed Patients Taking Place at Three
TrialNet Locations
What are the benefits of early intensive glucose control?
A new TrialNet study is testing whether early intensive glucose control—beginning within 7 days of diagnosis and continuing through the first 2 years—will help people retain their own insulin production for a longer period.

Rituximab helps preserve insulin production in people newly diagnosed
A recent TrialNet study proves that rituximab, a drug used to treat some types of cancer, also helps protect insulin-producing beta cells in people newly diagnosed with type 1 diabetes.

TrialNet study finds MMF/DZB therapy ineffective in saving beta cell function
A multi-center study, led by TrialNet researchers at 13 sites in North America and Europe, found that the drugs mycophenolate mofetil (MMF) and daclizumab (DZB) failed to halt loss of insulin-producing beta cells in patients newly diagnosed with type 1 diabetes.

GAD New Onset study meets enrollment goal in record time
The GAD New Onset Study recently met its enrollment goal of 126 patients. The goal was met in 13 months, exceeding expectations and demonstrating great interest in research by those newly diagnosed with type 1 diabetes. The GAD New Onset Study is exploring whether repeated injections of a protein called glutamic acid decarboxylase (GAD) will help newly diagnosed patients (diagnosed within 90 days) continue producing insulin. TrialNet is currently planning additional new onset studies that will be launched later this year.

TrialNet Studies Currently Enrolling

Natural History Study of the Development of Type 1 Diabetes: Screening and observing relatives of people with type 1 diabetes to learn more about how the disease occurs.

Oral Insulin for Prevention of Type 1 Diabetes Study: Testing whether a daily oral insulin capsule can prevent or delay type 1 diabetes in at-risk relatives of people with the disease.

Metabolic Control in New Onset Diabetes: Studying whether early intensive glucose control can help preserve insulin production.

Family of 241 inspires others to get screened for type 1 diabetes
A large extended family in New Hampshire is an inspiring example of how families of any size can take positive steps to fight type 1 diabetes. With 241 family members living in the United States, plus four babies on the way, the Ojalas are hosting their own type 1 diabetes family screening events with impressive results.

Meet the Principal Investigator: Tihamer Orban, M.D.
Type 1 Diabetes TrialNet is proud to work with the world's leading experts in type 1 diabetes. In this issue, we feature TrialNet principal investigator Tihamer Orban, M.D., associate investigator at Joslin Diabetes Clinic and an instructor at Harvard Medical School.

JDRF offers online service to connect patients with clinical trials
Juvenile Diabetes Research Foundation International (JDRF) recently introduced the Type 1 Diabetes Clinical Trials Connection, a resource to help people with type 1 diabetes find clinical trials of interest to them or family members. To learn more, visit https://trials.jdrf.org/patient/

TrialNet offers screening test kits by mail
If type 1 diabetes is in your family, you can order a test kit from a TrialNet Clinical Center and take it to a local doctor’s office or lab to collect a small blood sample. The kit is then sent back to the Clinical Center for processing and analysis by TrialNet's lab. To find out more, contact one of the TrialNet Clinical Centers listed here.